FDA Leadership Questions and Drug List Changes Stir Mixed Views

People currently seem to think the agency might shift a key substance to a new category on the bulk drug list by year end. Expectations appear to be leaning toward a split verdict, with a slight tilt favoring the change. The mood feels uncertain, neither strongly bullish nor bearish on the outcome.

When it comes to the commissioner nominee, the picture looks quite different. For a fall confirmation, the feeling overwhelmingly favors a no. Most voices doubt the timeline will work out. The skepticism appears to be strengthening as the calendar moves forward.

Looking at a late fall benchmark, the lean remains toward rejection. The doubt seems to be hardening rather than fading. Few appear to expect a smooth path through the process.

By early winter, the view turns even clearer. The consensus clearly favors a no outcome. The direction of feeling has moved from doubtful to firmly negative across the stretch of months.